NCT04959513

Brief Summary

When the practitioners have to place an implant, it is necessary to have a sufficient amount of bone. This study propose to manage clinical situations by an approach using guided bone regeneration using an L-PRF bone block (composite graft composed of a xenograft, a membrane from the patient's blood and a collagenous membrane) after a short healing period of 6 to 8 weeks after tooth extraction. Alveolar ridge changes will be evaluated regarding soft and hard tissues up to 6 months.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
15

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jan 2021

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 22, 2021

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

June 11, 2021

Completed
1 month until next milestone

First Posted

Study publicly available on registry

July 13, 2021

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2022

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2022

Completed
Last Updated

July 13, 2021

Status Verified

July 1, 2021

Enrollment Period

1.2 years

First QC Date

June 11, 2021

Last Update Submit

July 2, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • Gain in ridge width in millimeters

    Volumetric analysis of hard tissue using CBCT. They will be performed before extraction (T0), before guided bone regeneration (T1) and 6 months after regeneration before implant placement (T2). The CBCT done at T0 will be used as a reference for comparison with the CBCT T1 and T2. A high-resolution scanning protocol will be used with fixed exposure parameters and the CBCT will be adjusted to the target area to allow a significant reduction in irradiation dose. The DICOMs (Digital Imaging and Communication in Medicine) will be analysed using a dedicated application. The images taken at different times will be superimposed with an automatic algorithm and compared by 2D and 3D volumetric measurements.

    5 to 8 month after guided bone regeneration

Secondary Outcomes (5)

  • Volumetric changes of the soft tissue in millimeters

    5 to 8 month after guided bone regeneration

  • Need or not of an additional grafting procedure (yes or no)

    5 to 8 month after guided bone regeneration

  • Analysis of the implant's osseointegration (ISQ)

    up to 12 months

  • Patient reported outcomes mesures (VAS Scale)

    through study completion, an average of 1 year

  • Occurrence of an adverse effect

    through study completion, an average of 1 year

Study Arms (1)

GBR with L-PRF bone block

EXPERIMENTAL

Guided bone regeneration using Leukocyte and platelet-rich fibrin

Procedure: LPRF bone block

Interventions

Guided bone regeneration using an L-PRF bone block (composite graft composed of a xenograft, a membrane from the patient's blood and a collagenous membrane) after a short healing period of 6 to 8 weeks after tooth extraction

GBR with L-PRF bone block

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • To be over 18 years old.
  • Be in good general health.
  • Have at least one monoradicular tooth (premolar, canine or incisor) that must be extracted with the need for bone regeneration and one or more implants afterwards.
  • Have a DPSI (Dutch Periodontal Screening Index) ≤ 2.

You may not qualify if:

  • Being a smoker.
  • Have "active" periodontal problems, have a DPSI \> 2.
  • Have a contraindication to the insertion of an implant and/or oral surgery.
  • Have an active inflammatory and/or autoimmune disease of the oral cavity.
  • Treatment with immunosuppressants, corticosteroids or biphosphonates.
  • Have a history of cancer, radiotherapy or chemotherapy for cancer within the last 5 years.
  • Have insulin-dependent diabetes.
  • Have a blood disorder.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Clinique Universitaires Saint-Luc

Brussels, 1200, Belgium

RECRUITING

Study Officials

  • Jérôme Lasserre

    Cliniques universitaires Saint-Luc- Université Catholique de Louvain

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

June 11, 2021

First Posted

July 13, 2021

Study Start

January 22, 2021

Primary Completion

April 1, 2022

Study Completion

October 1, 2022

Last Updated

July 13, 2021

Record last verified: 2021-07

Data Sharing

IPD Sharing
Will not share

Locations